Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals Inc (NQ: MIRM )

43.48 -0.21 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 351,968
Open 43.92
Bid (Size) 38.66 (1)
Ask (Size) 44.05 (5)
Prev. Close 43.69
Today's Range 42.27 - 44.12
52wk Range 23.14 - 48.89
Shares Outstanding 38,297,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views
Via Benzinga

Performance

YTD
+44.84%
+44.84%
1 Month
+10.50%
+10.50%
3 Month
+5.43%
+5.43%
6 Month
+65.83%
+65.83%
1 Year
+35.87%
+35.87%

More News

Read More
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For Mirum Pharmaceuticals
Via Benzinga
We Tested Top Stocks; Here’s What’s Best For Your Money
Via Talk Markets
Analyst Expectations For Mirum Pharmaceuticals's Future
Via Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.